Lessons from tumor reversion for cancer treatment

Current Opinion in Oncology

Volumn 25, Issue 1, 2013, Pages 59-65

  Amson, Robert ^a   Karp, Judith E ^b   Telerman, Adam ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

p53; Sertraline; Thioridazine; TPT1 TCTP; Tumor reversion

Indexed keywords

PHENOTHIAZINE DERIVATIVE; PRESENILIN 1; SEROTONIN UPTAKE INHIBITOR; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER STEM CELL; CANCER THERAPY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TERATOCARCINOMA; UBIQUITINATION;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871986116     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835b7d21     Document Type: Review

References (57)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674
2. Telerman A, Amson R. The molecular programme of tumour reversion: The steps beyond malignant transformation. Nat Rev Cancer 2009; 9:206-216
3. Telerman A, Tuynder M, Dupressoir T, et al. A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci USA 1993; 90: 8702-8706
4. Amson RB, Nemani M, Roperch JP, et al. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: Activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc Natl Acad Sci USA 1996; 93:3953-3957
5. Nemani M, Linares-Cruz G, Bruzzoni-Giovanelli H, et al. Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc Natl Acad Sci USA 1996; 93:9039-9042
6. Linares-Cruz G, Bruzzoni-Giovanelli H, Alvaro V, et al. p21WAF-1 reorganizes the nucleus in tumor suppression. Proc Natl Acad Sci USA 1998; 95:1131- 1135
7. Roperch JP, Lethrone F, Prieur S, et al. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: Identification of common effectors with p53 and p21(Waf1). Proc Natl Acad Sci USA 1999; 96:8070-8073
8. Roperch JP, Alvaro V, Prieur S, et al. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med 1998; 4:835-838
9. Susini L, Passer BJ, Amzallag-Elbaz N, et al. Siah-1 binds and regulates the function of Numb. Proc Natl Acad Sci USA 2001; 98:15067-15072
10. Susini L, Besse S, Duflaut D, et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 2008; 15:1211-1220
11. Tuynder M, Susini L, Prieur S, et al. Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA 2002; 99:14976-14981
12. Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 2004; 101:15364- 15369
13. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med 2012; 18:91-99
14. Telerman A, Amson R, Hendrix MJ. Tumor reversion holds promise. Oncotarget 2010; 1:233-234
15. Braun AC. The reversal of tumor growth. Sci Am 1965; 213:75-83
16. Braun AC. A demonstration of the recovery of the crown-gall tumor cell with the use of complex tumors of single-cell origin. Proc Natl Acad Sci USA 1959; 45:932-938
17. Braun AC. Recovery of tumor cells from effects of the tumor-inducing principle in crown gall. Science 1951; 113:651-653
18. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964; 24:1544-1551
19. Pierce GB, Dixon FJ Jr. Testicular teratomas. I. Demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959; 12:573-583
20. Seilern-Aspang F, Kratochwil K. Induction and differentiation of an epithelial tumour in the newt (Triturus cristatus). J Embryol Exp Morphol 1962; 10:337- 356
21. Macpherson I. Reversion in Hamster cells transformed by Rous sarcoma virus. Science 1965; 148:1731-1733
22. Pollack RE, Green H, Todaro GJ. Growth control in cultured cells: Selection of sublines with increased sensitivity to contact inhibition and decreased tumorproducing ability. Proc Natl Acad Sci USA 1968; 60:126-133
23. Rabinowitz Z, Sachs L. Reversion of properties in cells transformed by polyoma virus. Nature 1968; 220:1203-1206
24. Noda M, Kitayama H, Matsuzaki T, et al. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc Natl Acad Sci USA 1989; 86:162-166
25. Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975; 72:3585-3589
26. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7:17- 23
27. Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137:231-245
28. Hendrix MJ, Seftor EA, Seftor RE, et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007; 7:246-255
29. Fiucci G, Beaucourt S, Duflaut D, et al. Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter. Proc Natl Acad Sci USA 2004; 101:3510-3515
30. Passer BJ, Nancy-Portebois V, Amzallag N, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc Natl Acad Sci USA 2003; 100:2284-2289
31. Amzallag N, Passer BJ, Allanic D, et al. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J Biol Chem 2004; 279:46104-46112
32. Lespagnol A, Duflaut D, Beekman C, et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ 2008; 15:1723- 1733
33. Cans C, Passer BJ, Shalak V, et al. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci USA 2003; 100:13892-13897
34. Liu H, Peng HW, Cheng YS, et al. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 2005; 25:3117-3126
35. Yang Y, Yang F, Xiong Z, et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 2005; 24:4778-4788
36. Chen SH, Wu PS, Chou CH, et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 2007; 18:2525-2532
37. Funston G, Goh W, Wei SJ, et al. Binding of translationally controlled tumour protein to the N-terminal domain of HDM2 is inhibited by Nutlin-3. PLoS One 2012; 7:e42642
38. Lin CJ, Robert F, Sukarieh R, et al. The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling. Cancer Res 2010; 70:3199-3208
39. Hsu YC, Chern JJ, Cai Y, et al. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007; 445:785- 788
40. Kang S, Dong SM, Kim BR, et al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 2012; 17:989-997
41. MacDonald ML, Lamerdin J, Owens S, et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2006; 2:329-337
42. Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149:1284-1297
43. Xu W, Tamim H, Shapiro S, et al. Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 2006; 7:301-308
44. Coogan PF, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf 2009; 18:1111-1114
45. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer 2011; 128:227-232
46. Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castration resistant prostate cancer. Mol Ther 2012. [Epub ahead of print]
47. Lo WY, Wang HJ, Chiu CW, Chen SF. miR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: From quantitative proteomics to posttranscriptional study. J Proteomics 2012. [Epub ahead of print]
48. Van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435:959-963
49. Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11:1565-1575
50. Tatarek J, Cullion K, Ashworth T, et al. Notch1 inhibition targets the leukemiainitiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 2011; 118:1579-1590
51. Huynh C, Poliseno L, Segura MF, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 2011; 6:e25264
52. Konishi J, Kawaguchi KS, Vo H, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007; 67:8051-8057
53. Ramakrishnan V, Ansell S, Haug J, et al. MRK003, a gamma-secretase inhibitor exhibits promising in vitro preclinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 2012; 26:340-348
54. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012; 209:437-444
55. Pandya K, Meeke K, Clementz AG, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 2011; 105:796-806
56. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase- 9 and inhibition of tumor invasion by the membraneanchored glycoprotein RECK. Proc Natl Acad Sci USA 1998; 95: 13221-13226
57. Murai R, Yoshida Y, Muraguchi T, et al. A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget 2010; 1:252-264.